Acute right heart failure in Waldenström macroglobulinemia: A case report

1 Thomas SK. Waldenstrom Macroglobulinemia —- 2021 update on management and future directions. Clin Lymphoma Myeloma Leuk. 2021: S2152-2650(21)02447-2. ThomasSK Waldenstrom Macroglobulinemia —- 2021 update on management and future directions Clin Lymphoma Myeloma Leuk 2021 S2152-2650(21)02447-2. Search in Google Scholar

2 Baďurová K, Gregorová J, Vlachová M, Krejčí M, Ševčíková S. Waldenstrom macroglobulinemia. Klin Onkol. 2021;34(6):428–33. BaďurováK GregorováJ VlachováM KrejčíM ŠevčíkováS Waldenstrom macroglobulinemia Klin Onkol 2021 34 6 428 33 10.48095/ccko202142834911327 Search in Google Scholar

3 Gertz MA. Waldenstrom macroglobulinemia: 2021 update on diagnosis, risk stratification, and management. Am J Hematol. 2021;96(2):258–69. GertzMA Waldenstrom macroglobulinemia: 2021 update on diagnosis, risk stratification, and management Am J Hematol 2021 96 2 258 69 10.1002/ajh.2608233368476 Search in Google Scholar

4 McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726. McDonaghTA MetraM AdamoM GardnerRS BaumbachA BöhmM BurriH ButlerJ ČelutkienėJ ChioncelO ClelandJGF CoatsAJS Crespo-LeiroMG FarmakisD GilardM HeymansS HoesAW JaarsmaT JankowskaEA LainscakM LamCSP LyonAR McMurrayJJV MebazaaA MindhamR MunerettoC Francesco PiepoliM PriceS RosanoGMC RuschitzkaF Kathrine SkibelundA ESC Scientific Document Group 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Eur Heart J 2021 42 36 3599 726 10.1093/eurheartj/ehab36834447992 Search in Google Scholar

5 Kwaan HC. Hyperviscosity in plasma cell dyscrasias. Clin Hemorheol Microcirc. 2013;55(1):75–83. KwaanHC Hyperviscosity in plasma cell dyscrasias Clin Hemorheol Microcirc 2013 55 1 75 83 10.3233/CH-13169123455837 Search in Google Scholar

6 Consuegra A, PJ Marcos, R Vazquez, Pombo J, Deben G, Verea-Hernando H. Diffuse interstitial lung disease as a first manifestation of Waldenström macroglobulinemia: case report and review of the literature. Arch Bronconeumol. 2014;50(4):151–3. ConsuegraA MarcosPJ VazquezR PomboJ DebenG Verea-HernandoH Diffuse interstitial lung disease as a first manifestation of Waldenström macroglobulinemia: case report and review of the literature Arch Bronconeumol 2014 50 4 151 3 10.1016/j.arbres.2013.05.00924629759 Search in Google Scholar

7 Green AP, Gonzalez AC, Alperin JB, Burner JD, Yates SG. The utility of therapeutic plasma exchange in hyperviscosity syndrome associated with juvenile rheumatoid arthritis: A case report. J Clin Apher. 2021;36(4):658–63. GreenAP GonzalezAC AlperinJB BurnerJD YatesSG The utility of therapeutic plasma exchange in hyperviscosity syndrome associated with juvenile rheumatoid arthritis: A case report J Clin Apher 2021 36 4 658 63 10.1002/jca.2190333945169 Search in Google Scholar

8 Hernández-Molina G, Bermúdez-Bermejo P. Hyperviscosity in primary Sjogren's syndrome: clinical implications. Int J Rheum Dis. 2017;20(1):84–9. Hernández-MolinaG Bermúdez-BermejoP Hyperviscosity in primary Sjogren's syndrome: clinical implications Int J Rheum Dis 2017 20 1 84 9 10.1111/1756-185X.1275126807556 Search in Google Scholar

9 Schatz MJ, Wilkins CS, Otero-Marquez O, Chui TYP, Rosen RB, Gupta M. Multimodal imaging of Waldenstrom macroglobulinemia-associated hyperviscosity-related retinopathy treated with plasmapheresis. Case Rep Ophthalmol Med. 2021;2021:6816195. SchatzMJ WilkinsCS Otero-MarquezO ChuiTYP RosenRB GuptaM Multimodal imaging of Waldenstrom macroglobulinemia-associated hyperviscosity-related retinopathy treated with plasmapheresis Case Rep Ophthalmol Med 2021 2021 6816195 10.1155/2021/6816195869500434956683 Search in Google Scholar

10 Kikukawa Y, Yamamura-Fujimoto A, Endo S, Miyagawa E, Kawano Y, Ueno S, Mitsuya H, Hata H, Okuno Y. Successful treatment of Bing-Neel syndrome accompanying Waldenstrom's macroglobulinemia with R-MPV: a case report. J Clin Exp Hematop. 2015;55(2):113–9. KikukawaY Yamamura-FujimotoA EndoS MiyagawaE KawanoY UenoS MitsuyaH HataH OkunoY Successful treatment of Bing-Neel syndrome accompanying Waldenstrom's macroglobulinemia with R-MPV: a case report J Clin Exp Hematop 2015 55 2 113 9 10.3960/jslrt.55.11326490525 Search in Google Scholar

11 Kudo N, Usui M, Nakabo Y, Yoshida KI, Miki K, Osafune T, Nishimura K, Imashuku S. Waldenstrom's macroglobulinemia: a report of two cases, one with severe retinopathy and one with renal failure. Case Rep Hematol. 2017;2017:3732902. KudoN UsuiM NakaboY YoshidaKI MikiK OsafuneT NishimuraK ImashukuS Waldenstrom's macroglobulinemia: a report of two cases, one with severe retinopathy and one with renal failure Case Rep Hematol 2017 2017 3732902 10.1155/2017/3732902568459529225979 Search in Google Scholar

12 Mihalcea DJ, Florescu M, Vinereanu D. Mechanisms and genetic susceptibility of chemotherapy-induced cardiotoxicity in patients with breast cancer. Am J Ther. 2017;24(1):e3–e11. MihalceaDJ FlorescuM VinereanuD Mechanisms and genetic susceptibility of chemotherapy-induced cardiotoxicity in patients with breast cancer Am J Ther 2017 24 1 e3 e11 10.1097/MJT.000000000000045327145188 Search in Google Scholar

13 Mihalcea D, Florescu M, Bruja R, Patrascu N, Vladareanu AM, Vinereanu D. 3D echocardiography, arterial stiffness, and biomarkers in early diagnosis and prediction of CHOP-induced cardiotoxicity in non-Hodgkin's lymphoma. Sci Rep. 2020;10(1):18473. MihalceaD FlorescuM BrujaR PatrascuN VladareanuAM VinereanuD 3D echocardiography, arterial stiffness, and biomarkers in early diagnosis and prediction of CHOP-induced cardiotoxicity in non-Hodgkin's lymphoma Sci Rep 2020 10 1 18473 10.1038/s41598-020-75043-3759519533116212 Search in Google Scholar

14 Florescu M, Magda LS, Enescu OA, Jinga D, Vinereanu D. Early detection of epirubicin-induced cardiotoxicity in patients with breast cancer. J Am Soc Echocardiogr. 2014;27(1):83–92. FlorescuM MagdaLS EnescuOA JingaD VinereanuD Early detection of epirubicin-induced cardiotoxicity in patients with breast cancer J Am Soc Echocardiogr 2014 27 1 83 92 10.1016/j.echo.2013.10.00824268372 Search in Google Scholar

15 Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM; ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768–2801. ZamoranoJL LancellottiP Rodriguez MuñozD AboyansV AsteggianoR GalderisiM HabibG LenihanDJ LipGYH LyonAR Lopez FernandezT MohtyD PiepoliMF TamargoJ TorbickiA SuterTM ESC Scientific Document Group 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) Eur Heart J 2016 37 36 2768 2801 10.1093/eurheartj/ehw21127567406 Search in Google Scholar

16 Pancheri E, Guglielmi V, Wilczynski GM, Malatesta M, Tonin P, Tomelleri G, Nowis D, Vattemi G. Non-hematologic toxicity of bortezomib in multiple myeloma: the neuromuscular and cardiovascular adverse effects. Cancers (Basel). 2020;12(9):2540. PancheriE GuglielmiV WilczynskiGM MalatestaM ToninP TomelleriG NowisD VattemiG Non-hematologic toxicity of bortezomib in multiple myeloma: the neuromuscular and cardiovascular adverse effects Cancers (Basel) 2020 12 9 2540 10.3390/cancers12092540756397732906684 Search in Google Scholar

17 Atalay F, Gulmez O, Ozsancak Ugurlu A. Cardiotoxicity following cyclophosphamide therapy: a case report. J Med Case Rep. 2014;8:252. AtalayF GulmezO Ozsancak UgurluA Cardiotoxicity following cyclophosphamide therapy: a case report J Med Case Rep 2014 8 252 10.1186/1752-1947-8-252410621325023062 Search in Google Scholar

18 Katayama M, Imai Y, Hashimoto H, Kurata M, Nagai K, Tamita K, Morioka S, Furukawa Y. Fulminant fatal cardiotoxicity following cyclophosphamide therapy. J Cardiol. 2009;54(2):330–4. KatayamaM ImaiY HashimotoH KurataM NagaiK TamitaK MoriokaS FurukawaY Fulminant fatal cardiotoxicity following cyclophosphamide therapy J Cardiol 2009 54 2 330 4 10.1016/j.jjcc.2009.01.00619782276 Search in Google Scholar

19 de Salvi Guimarães F, de Moraes WM, Bozi LH, Souza PR, Antonio EL, Bocalini DS, Tucci PJ, Ribeiro DA, Brum PC, Medeiros A. Dexamethasone-induced cardiac deterioration is associated with both calcium handling abnormalities and calcineurin signaling pathway activation. Mol Cell Biochem. 2017;424(1–2):87–98. de Salvi GuimarãesF de MoraesWM BoziLH SouzaPR AntonioEL BocaliniDS TucciPJ RibeiroDA BrumPC MedeirosA Dexamethasone-induced cardiac deterioration is associated with both calcium handling abnormalities and calcineurin signaling pathway activation Mol Cell Biochem 2017 424 1–2 87 98 10.1007/s11010-016-2846-327761848 Search in Google Scholar

20 Ng KH, Dearden C, Gruber P. Rituximab-induced Takotsubo syndrome: more cardiotoxic than it appears? BMJ Case Rep. 2015;2015:bcr2014208203. NgKH DeardenC GruberP Rituximab-induced Takotsubo syndrome: more cardiotoxic than it appears? BMJ Case Rep 2015 2015 bcr2014208203. 10.1136/bcr-2014-208203436903625733089 Search in Google Scholar

21 Lazarevic VLj, Liljeholm M, Forsberg K, Söderberg S, Wahlin A. Fludarabine, cyclophosphamide and rituximab (FCR) induced pulmonary hypertension in Waldenstrom macroglobulinemia. Leuk Lymphoma. 2008;49(6):1209–11. LazarevicVLj LiljeholmM ForsbergK SöderbergS WahlinA Fludarabine, cyclophosphamide and rituximab (FCR) induced pulmonary hypertension in Waldenstrom macroglobulinemia Leuk Lymphoma 2008 49 6 1209 11 10.1080/1042819080200771818452089 Search in Google Scholar

22 Montrone D, Correale M, Franzese MG, Ieva R, Di Biase M, Capalbo SF. Pulmonary arterial hypertension in a chronic lymphocytic leukemia patient in treatment with rituximab. J Cardiovasc Med (Hagerstown). 2015;16 Suppl 1:S65. MontroneD CorrealeM FranzeseMG IevaR Di BiaseM CapalboSF Pulmonary arterial hypertension in a chronic lymphocytic leukemia patient in treatment with rituximab J Cardiovasc Med (Hagerstown) 2015 16 Suppl 1 S65 10.2459/JCM.0b013e3283621adf25643063 Search in Google Scholar